3:45 PM
 | 
May 14, 2019
 |  BC Extra  |  Politics & Policy

Mylan calls for streamlined interchangeable insulin pathway

A streamlined approach to interchangeable insulins will help to eliminate burdensome requirements that are hindering the therapies’ development, according to a Mylan executive.

Abhijit Barve, head of global clinical research at Mylan N.V. (NASDAQ:MYL), said that a single immunogenicity study with relatively few patients is sufficient to demonstrate interchangeability as opposed to two trials outlined in FDA biosimilars guidance published in...

Read the full 287 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >